CN102762208A - 作为ck2抑制剂的吡唑嘧啶和相关杂环 - Google Patents

作为ck2抑制剂的吡唑嘧啶和相关杂环 Download PDF

Info

Publication number
CN102762208A
CN102762208A CN2010800630542A CN201080063054A CN102762208A CN 102762208 A CN102762208 A CN 102762208A CN 2010800630542 A CN2010800630542 A CN 2010800630542A CN 201080063054 A CN201080063054 A CN 201080063054A CN 102762208 A CN102762208 A CN 102762208A
Authority
CN
China
Prior art keywords
optionally substituted
compound
alkyl
compounds
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800630542A
Other languages
English (en)
Chinese (zh)
Inventor
M·哈达齐
J·A·特兰
F·皮埃尔
C·F·里根
N·B·拉法尔勒
S·拉伍拉
D·M·利克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CN102762208A publication Critical patent/CN102762208A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2010800630542A 2009-12-04 2010-11-15 作为ck2抑制剂的吡唑嘧啶和相关杂环 Pending CN102762208A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26680109P 2009-12-04 2009-12-04
US61/266,801 2009-12-04
US35416510P 2010-06-11 2010-06-11
US61/354,165 2010-06-11
PCT/US2010/056712 WO2011068667A1 (en) 2009-12-04 2010-11-15 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors

Publications (1)

Publication Number Publication Date
CN102762208A true CN102762208A (zh) 2012-10-31

Family

ID=44115232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800630542A Pending CN102762208A (zh) 2009-12-04 2010-11-15 作为ck2抑制剂的吡唑嘧啶和相关杂环

Country Status (14)

Country Link
US (2) US8575177B2 (cg-RX-API-DMAC7.html)
EP (1) EP2509602B9 (cg-RX-API-DMAC7.html)
JP (1) JP5802676B2 (cg-RX-API-DMAC7.html)
KR (1) KR101851130B1 (cg-RX-API-DMAC7.html)
CN (1) CN102762208A (cg-RX-API-DMAC7.html)
AU (1) AU2010326268B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012013508A2 (cg-RX-API-DMAC7.html)
CA (1) CA2782684C (cg-RX-API-DMAC7.html)
ES (1) ES2629170T3 (cg-RX-API-DMAC7.html)
IL (1) IL220086B (cg-RX-API-DMAC7.html)
PL (1) PL2509602T3 (cg-RX-API-DMAC7.html)
RU (1) RU2607453C2 (cg-RX-API-DMAC7.html)
SG (1) SG181507A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011068667A1 (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103360399A (zh) * 2013-08-02 2013-10-23 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
CN104844605A (zh) * 2014-02-13 2015-08-19 生华生物科技股份有限公司 吡唑并嘧啶前药及其制备方法和应用
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN106103445A (zh) * 2014-02-21 2016-11-09 癌症研究技术有限公司 作为cdk抑制剂的吡唑并[1,5‑a]嘧啶‑5,7‑二胺化合物和它们的治疗用途
CN106170489A (zh) * 2014-05-28 2016-11-30 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
CN107188901A (zh) * 2017-05-27 2017-09-22 无锡捷化医药科技有限公司 一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法
CN116075502A (zh) * 2020-03-30 2023-05-05 生华生物科技股份有限公司 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555261T3 (es) * 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
WO2012170827A2 (en) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2013161567A1 (ja) * 2012-04-27 2013-10-31 新日鐵住金株式会社 継目無鋼管及びその製造方法
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
EP4534538A3 (en) 2012-12-07 2025-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
AR094664A1 (es) 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
RU2719583C2 (ru) 2014-06-05 2020-04-21 Вертекс Фармасьютикалз Инкорпорейтед Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
JP2017537940A (ja) * 2014-12-10 2017-12-21 マサチューセッツ インスティテュート オブ テクノロジー 増殖性疾患の処置に有用な融合１，３−アゾール誘導体
CA2973432C (en) * 2015-01-23 2023-04-04 Glaxosmithkline Intellectual Property Development Limited Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
KR20180107261A (ko) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도
CN109562111B (zh) * 2016-06-24 2023-04-04 北极星药业股份有限公司 Ck2抑制剂，其组合物及方法
AU2018256459B2 (en) 2017-04-21 2023-12-07 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
BR112020001278A2 (pt) 2017-07-28 2020-07-21 Yuhan Corporation processo aprimorado para preparar derivados de aminopirimidina
EP3658557B1 (en) 2017-07-28 2024-06-05 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
JP7385658B2 (ja) 2018-10-30 2023-11-22 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物、組成物、および方法
CN112500416B (zh) * 2019-07-30 2021-12-17 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类化合物中间体的制备方法
EP4065582B1 (en) 2019-11-26 2025-02-19 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
KR102337404B1 (ko) * 2020-01-03 2021-12-10 연세대학교 산학협력단 조직 재생용 조성물
CN116323569A (zh) * 2020-09-15 2023-06-23 田边三菱制药株式会社 三嗪化合物的盐、其晶型及制造方法
CA3172939A1 (en) * 2021-01-09 2022-07-14 Bugworks Research, Inc. Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist
US12343421B2 (en) * 2021-11-01 2025-07-01 Solaana MD LLC Vitamin D base layer
WO2024187126A1 (en) * 2023-03-09 2024-09-12 Aquinnah Pharmaceuticals, Inc. Inhibitors of tdp-43 and tau aggregation
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7071218B2 (en) * 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
US7206308B2 (en) * 2001-12-22 2007-04-17 International Business Machines Corporation Method of providing a non-blocking routing network
JP2005530739A (ja) * 2002-04-19 2005-10-13 セルラー ジェノミクス，インコーポレーテッド イミダゾ［１，２−ａ］ピラジン−８−イルアミン、生成方法、および使用方法
WO2004006916A1 (en) * 2002-07-10 2004-01-22 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
PL374718A1 (en) * 2002-07-10 2005-10-31 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497544C (en) * 2002-09-04 2010-11-02 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
AU2003225669A1 (en) * 2002-09-26 2004-04-19 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MXPA05008955A (es) * 2003-02-28 2006-02-22 Teijin Pharma Ltd Derivados de pirazolo [1,5-a] pirimidina.
PE20051128A1 (es) * 2004-02-25 2006-01-16 Schering Corp Pirazolotriazinas como inhibidores de quinasa
US7842698B2 (en) * 2004-09-03 2010-11-30 Merck Serono S.A. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
EP2046333A4 (en) * 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
FR2907120B1 (fr) * 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
MX2011012369A (es) * 2009-05-20 2012-03-16 Cylene Pharmaceuticals Inc Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103360399A (zh) * 2013-08-02 2013-10-23 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN104844605A (zh) * 2014-02-13 2015-08-19 生华生物科技股份有限公司 吡唑并嘧啶前药及其制备方法和应用
CN106103445A (zh) * 2014-02-21 2016-11-09 癌症研究技术有限公司 作为cdk抑制剂的吡唑并[1,5‑a]嘧啶‑5,7‑二胺化合物和它们的治疗用途
CN106103445B (zh) * 2014-02-21 2019-08-09 癌症研究技术有限公司 作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途
CN106170489A (zh) * 2014-05-28 2016-11-30 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
CN106170489B (zh) * 2014-05-28 2019-05-03 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
CN107188901A (zh) * 2017-05-27 2017-09-22 无锡捷化医药科技有限公司 一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法
CN116075502A (zh) * 2020-03-30 2023-05-05 生华生物科技股份有限公司 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
CN116075502B (zh) * 2020-03-30 2024-04-12 生华生物科技股份有限公司 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法

Also Published As

Publication number Publication date
RU2012127792A (ru) 2014-08-10
IL220086A0 (en) 2012-09-24
PL2509602T3 (pl) 2017-08-31
ES2629170T3 (es) 2017-08-07
BR112012013508A2 (pt) 2019-09-24
SG181507A1 (en) 2012-07-30
US9303033B2 (en) 2016-04-05
AU2010326268B2 (en) 2016-11-03
EP2509602A1 (en) 2012-10-17
US20110152240A1 (en) 2011-06-23
EP2509602B9 (en) 2017-11-01
JP5802676B2 (ja) 2015-10-28
US20140094448A1 (en) 2014-04-03
WO2011068667A1 (en) 2011-06-09
EP2509602B1 (en) 2017-01-25
EP2509602A4 (en) 2013-10-09
IL220086B (en) 2018-02-28
JP2013512903A (ja) 2013-04-18
AU2010326268A1 (en) 2012-07-26
CA2782684A1 (en) 2011-06-09
RU2607453C2 (ru) 2017-01-10
KR20130067486A (ko) 2013-06-25
CA2782684C (en) 2018-09-04
US8575177B2 (en) 2013-11-05
KR101851130B1 (ko) 2018-04-23

Similar Documents

Publication Publication Date Title
CN102762208A (zh) 作为ck2抑制剂的吡唑嘧啶和相关杂环
US7531539B2 (en) Pyrrolotriazine kinase inhibitors
CN102625803A (zh) 药学上有用的杂环-取代的内酰胺
KR101532256B1 (ko) 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
US7834019B2 (en) Substituted pyrazolo[3,4-d]pyrimidinone derivatives
US8445676B2 (en) Pyrrolotriazine kinase inhibitors
CN102014914A (zh) 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
US20090062288A1 (en) Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
JP7093306B2 (ja) ＰＤＥ１阻害剤としての１，５－ジヒドロ－４Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－４－オン及び１，５－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］ピリジン－４－オン
CN102647904A (zh) 新型三环蛋白激酶调节剂
CN101883774A (zh) 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
IL301180A (en) Use of pyrazolopyrimidine derivatives for the treatment of P13K-related disorders
CN101917995A (zh) Polo样激酶抑制剂
CN102647906A (zh) 三环化合物及其药学用途
WO2012170827A2 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
TW201602115A (zh) 新穎二環性或三環性雜環化合物
TW201348240A (zh) 噻吩并嘧啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121031